LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world.
The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe.
A German Federal Court decision has given patent applicants in the life sciences field plenty to think about, as Wolfgang Bublak and Axel Berger explain.
With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit.
The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products.
A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR.
Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.
At some offices, the passage of a patent through the system is not quite as fast as applicants might hope—and at others it may be quicker than they would like. Matt Smith and Jonathan Wills outline the situation.
The European Patent Office grants approximately 6,000 biotechnology patents per year. LSIPR spoke to Victor Kaas, director of biotechnology at the office, about how it faces the unique challenges of the industry.
The law of patents and SPCs has yet to be tested in the context of medicines which can be used to treat specific groups of patients, as Paul England explains.